INTRODUCTION: Few studies have sought to identify specific genetic markers associated with cigarettes per day (CPD) during adolescence and young adulthood, the period of greatest vulnerability for the development of nicotine dependence. METHODS: We used a longitudinal design to investigate the effect of neuronal nicotinic acetylcholine receptor (CHRN) subunit genes on CPD from 15 to 21 years of age in young smokers of European descent (N = 439, 59% female). The number of CPD typically smoked during the previous 30 days was self-reported. Single nucleotide polymorphisms (SNPs) from CHRN genes were genotyped using DNA extracted from saliva samples collected at the 5-year assessment. Mixed-model analyses of SNP effects were computed across age at the time of assessment using log-transformed CPD as the phenotype. Data from the 1000 Genomes Project were used to clarify the architecture of CHRN genes to inform SNP selection and interpretation of results. RESULTS: CPD was associated with a CHRNB3A6 region tagged by rs2304297, with CHRNA5A3B4 haplotype C (tagged by rs569207), and with the CHRNA2 SNP rs2271920, ps < .004. The reliability of single-SNP associations was supported by the correspondence between a more extensive set of SNP signals and the underlying genetic architecture. The 3 signals identified in this study appear to make independent contributions to CPD, and their combined effect accounts for 5.5% of the variance in log-transformed CPD. CONCLUSIONS: Level of CPD during adolescence and young adulthood is associated with CHRNB3A6, CHRNA5A3B4, and CHRNA2.
INTRODUCTION: Few studies have sought to identify specific genetic markers associated with cigarettes per day (CPD) during adolescence and young adulthood, the period of greatest vulnerability for the development of nicotine dependence. METHODS: We used a longitudinal design to investigate the effect of neuronal nicotinic acetylcholine receptor (CHRN) subunit genes on CPD from 15 to 21 years of age in young smokers of European descent (N = 439, 59% female). The number of CPD typically smoked during the previous 30 days was self-reported. Single nucleotide polymorphisms (SNPs) from CHRN genes were genotyped using DNA extracted from saliva samples collected at the 5-year assessment. Mixed-model analyses of SNP effects were computed across age at the time of assessment using log-transformed CPD as the phenotype. Data from the 1000 Genomes Project were used to clarify the architecture of CHRN genes to inform SNP selection and interpretation of results. RESULTS: CPD was associated with a CHRNB3A6 region tagged by rs2304297, with CHRNA5A3B4 haplotype C (tagged by rs569207), and with the CHRNA2 SNP rs2271920, ps < .004. The reliability of single-SNP associations was supported by the correspondence between a more extensive set of SNP signals and the underlying genetic architecture. The 3 signals identified in this study appear to make independent contributions to CPD, and their combined effect accounts for 5.5% of the variance in log-transformed CPD. CONCLUSIONS: Level of CPD during adolescence and young adulthood is associated with CHRNB3A6, CHRNA5A3B4, and CHRNA2.
Authors: Christopher S Carlson; Michael A Eberle; Mark J Rieder; Qian Yi; Leonid Kruglyak; Deborah A Nickerson Journal: Am J Hum Genet Date: 2003-12-15 Impact factor: 11.025
Authors: Robin Mermelstein; Suzanne M Colby; Christi Patten; Alexander Prokhorov; Richard Brown; Mark Myers; William Adelman; Karen Hudmon; Paul McDonald Journal: Nicotine Tob Res Date: 2002-11 Impact factor: 4.244
Authors: John P Rice; Sarah M Hartz; Arpana Agrawal; Laura Almasy; Siiri Bennett; Naomi Breslau; Kathleen K Bucholz; Kimberly F Doheny; Howard J Edenberg; Alison M Goate; Victor Hesselbrock; William B Howells; Eric O Johnson; John Kramer; Robert F Krueger; Samuel Kuperman; Cathy Laurie; Teri A Manolio; Rosalind J Neuman; John I Nurnberger; Bernice Porjesz; Elizabeth Pugh; Erin M Ramos; Nancy Saccone; Scott Saccone; Marc Schuckit; Laura J Bierut Journal: Addiction Date: 2012-06-15 Impact factor: 6.526
Authors: Janet Audrain-McGovern; Daniel Rodriguez; Adam M Leventhal; Jocelyn Cuevas; Kelli Rodgers; Joseph Sass Journal: Nicotine Tob Res Date: 2012-03-01 Impact factor: 4.244
Authors: Weihai Zhan; Lisa C Dierker; Jennifer S Rose; Arielle Selya; Robin J Mermelstein Journal: Nicotine Tob Res Date: 2012-03-15 Impact factor: 4.244
Authors: Arielle S Selya; Lisa C Dierker; Jennifer S Rose; Donald Hedeker; Xianming Tan; Runze Li; Robin J Mermelstein Journal: Drug Alcohol Depend Date: 2012-09-17 Impact factor: 4.492
Authors: Danice K Eaton; Laura Kann; Steve Kinchen; Shari Shanklin; Katherine H Flint; Joseph Hawkins; William A Harris; Richard Lowry; Tim McManus; David Chyen; Lisa Whittle; Connie Lim; Howell Wechsler Journal: MMWR Surveill Summ Date: 2012-06-08
Authors: Dale S Cannon; Robin J Mermelstein; Tait R Medina; Oksana Pugach; Donald Hedeker; Robert B Weiss Journal: Nicotine Tob Res Date: 2015-11-05 Impact factor: 4.244
Authors: Dale S Cannon; Tait R Medina; Robin J Mermelstein; Donald Hedeker; Amanda V Bakian; Hilary Coon; Edwin H Cook; Cindy Hamil; Robert B Weiss Journal: Nicotine Tob Res Date: 2015-03-05 Impact factor: 4.244
Authors: Arielle S Selya; Dale S Cannon; Robert B Weiss; Lauren S Wakschlag; Jennifer S Rose; Lisa Dierker; Donald Hedeker; Robin J Mermelstein Journal: Addict Behav Date: 2018-05-03 Impact factor: 3.913
Authors: Gerald A Deehan; Sheketha R Hauser; Bruk Getachew; R Aaron Waeiss; Eric A Engleman; Christopher P Knight; William J McBride; William A Truitt; Richard L Bell; Zachary A Rodd Journal: Psychopharmacology (Berl) Date: 2018-07-24 Impact factor: 4.530
Authors: Oksana Pugach; Dale S Cannon; Robert B Weiss; Donald Hedeker; Robin J Mermelstein Journal: Nicotine Tob Res Date: 2017-04-01 Impact factor: 4.244
Authors: Whitney E Melroy-Greif; Matthew A Simonson; Robin P Corley; Sharon M Lutz; John E Hokanson; Marissa A Ehringer Journal: Nicotine Tob Res Date: 2017-04-01 Impact factor: 4.244
Authors: Hilary Coon; Thomas M Piasecki; Edwin H Cook; Diane Dunn; Robin J Mermelstein; Robert B Weiss; Dale S Cannon Journal: Alcohol Clin Exp Res Date: 2014-01-15 Impact factor: 3.455